Differences in surface expression of NspA among Neisseria meningitidis group B strains

Infection and Immunity

Volumn 67, Issue 11, 1999, Pages 5664-5675

  Moe, Gregory R ^a   Tan, Siqi ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; POLYSACCHARIDE; RECOMBINANT ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; BACTERIOLYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CONSERVATION; IMMUNITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

EID: 0032706010     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.11.5664-5675.1999     Document Type: Article

References (69)

1. Altschul, S. F., T. L. Madden, A, A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.
2. Azmi, F. H., A. H. Lucas, H. L. Spiegelberg, and D. M. Granoff. 1995. Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect. Immun. 63:1906-1913.
3. Banerjee-Bhatnagar, N., and C. E. Frasch. 1990. Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilo-dalton transferrin receptor, and their potential for use as vaccines. Infect. Immun. 58:2875-2881.
4. Barenkamp, S. J., R. S. Munson, Jr., and D. M. Granoff. 1981. Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles. J. Infect. Dis. 143:668-676.
5. Bjune, G., J. K. Gronnesby, E. A. Hoiby, O. Closs, and H. Nokleby. 1991. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. 14:125-130.
6. Borrow, R., S. Clark, F. Sadler, A. J. Fox, P. van der Ley, and E. R. ran der Voort. 1998. Effect of sequence variation in the meningococcal PorA OMP on the immungenicity of a recombinant PorA meningococcal OMV vaccine in UK infants, p. 178. In Abstracts of the Eleventh International Pathogenic Neisseria Conference. Editions E.D.K.
7. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, et al. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821-829.
8. Campagne, G., A. Garba, P. Fabre, G. Carlone, B. Ryall, J. Froeschle, A. Schuchat, D. Boulanger, P. Briantais, and J. P. Chippaux. 1997. Safety and immunogenicity of three doses of a N. meningitidis A/C diphtheria conjugate vaccine in infants in Niger, p. 192. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Caugant, D. A., P. Bol, E. A. Holby, H. C. Zanen, and L. O. Froholm. 1990. Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986. J. Infect. Dis. 162:867-874.
10. Centers for Disease Control and Prevention. 1998. Outbreaks of group B meningococcal disease - Florida, 1995 and 1997. Morbid. Mortal. Weekly Rep. 47:833-837.
11. Centers for Disease Control and Prevention. 1995. Serogroup B meningococcal disease - Oregon, 1994. Morbid. Mortal. Weekly Rep. 44:121-124.
12. Christodoulides, M., J. L. Brooks, E. Rattue, and J. E. Heckels. 1998 Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144:3027-3037.
13. Corn, P. G., J. Anders, A. K. Takala, H. Käjhty, and S. K. Hoiseth. 1993. Genes involved in Haemophilus influenzae type b capsule expression are frequently amplified. J. Infect. Dis. 167:356-364.
14. Davis, B. D., R. Dulbecco, H. N. Elsen, and H. S. Ginsberg. 1980. The neisseriae, p. 635-644. In E. C. Gotschlich (ed.), Microbiology, 3rd ed., Harper. New York, N.Y.
15. Devi, S. J., W. D. Zollinger, P. J. Snoy, J. Y. Tai, P. Costantini, F. Norelli, R. Rappuoli, and C. E. Frasch. 1997. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. 65:1045-1052.
16. Fairlej, C. K., N. Begg, R. Borrow, A. J. Fox, D. M. Jones, and K. Cartwight. 1996. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1360-1363.
17. Finne, J., D. Bitter-Suermann, C. Goridis, and U. Finne. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extra-neural tissues. J. Immunol. 138:4402-4407.
18. Frasch, C. E. 1995. Meningococcal vaccines: past, present and future, p. 245-283. In K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons, Inc., New York, N.Y.
19. Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 7:504-510.
20. Fusco, P. C., F. Michon, J. Y. Tai, and M. S. Blake. 1997. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175:364-372.
21. Granoff, D. M., A. Bartoloni, S. Ricci, E. Gallo, D. Rosa, N. Ravenscroft, V. Guarnieri, R. C. Seid, A. Shan, W. R. Usinger, S. Tan, Y. E. McHugh, and G. R. Moe. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160:5028-5036.
22. Granoff, D. M., S. K. Kelsey, H. A. Bijlmer, L. Van Alphen, J. Dankert, R. E. Mandrell, F. H. Azmi, and R. J. Scholten. 1995. Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Clin. Diagn. Lab. Immunol. 2:574-582.
23. Hayrinen, J., H. Jennings, H. V. Raff, G. Rougon, N. Hanai, R. Gerardy-Schahn, and J. Finne. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis. 171:1481-1490.
24. Idänpään-Heikkilä, I., S. Muttilainen, E. Wahlström, L. Saarinen, M. Leinonen, M. Sarvas, and P. H. Mäkelä. 1995. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine 13:1501-1508.
25. Jennings, H. J., A. Gamian, and F. E. Ashton. 1987. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 165:1207-1211.
26. Jennings, H. J., and C. Lugowski. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
27. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. Leach, A., P. A. Twumasi, S. Kumah, W. S. Banya, S. Jafar, B. D. Forrest, D. M. Granoff, D. E. LiButti, G. M. Carlone, L. B. Pais, C. V. Broome, and B. M. Greenwood. 1997. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200-204.
29. Lieberman, J. M., S. S. Chiu, V. K. Wong, S. Partidge, S. J. Chang, C. Y. Chiu, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. JAMA 275:1499-1503.
30. Lieberman, J. M., V. K. Wong, S. Partridge, S.-J. Chang, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Bivalent A/C meningococcal conjugate vaccine in toddlers: persistence of antibodies and response to a polysaccharide vaccine booster, p. 231. In Abstracts of the Tenth International Pathogenic Neisseria conference.
31. Lissolo, L., G. Maitre-Wilmotte, P. Dumas, M. Mignon, B. Danve, and M. J. Quentin-Millet. 1995. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63:884-890.
32. MacDonald, N. E., S. A. Halperin, B. J. Law, B. Forrest, L. E. Danzig, and D. M. Granoff. 1998. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280:1685-1689.
33. Maiden, M. C., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman, and B. G. Spratt. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA 95:3140-3145.
34. Malorny, B., G. Morelli, B. Kusecek, J. Kolberg, and M. Achtman. 1998. Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J. Bacteriol. 180:1323-1330.
35. Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly alpha 2-→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis sero-group B. J. Infect. Dis. 172:1279-1289.
36. Martin, D., N. Cadieux, J. Hamel, and B. R. Brodeur. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1173-1183.
37. Martin, D., C. R. Roiux, A. Villeneuve, J. Hamel, and B. R. Brodeur. 1998. Induction of cross-reactive bactericidal and protective antibodies in animals immunized with purified recombinant meningococcal NspA protein, p. 198. In Abstracts of the Eleventh International Pathogenic Neisseria Conference. Editions E.D.K.
38. Merker, P., J. Tommassen, B. Kusecek, M. Virji, D. Sesardic, and M. Achtman. 1997. Two-dimensional structure of the Opc invasin from Neisseria meningitidis. Mol. Microbiol. 23:281-293.
39. Musacchio, A., T. Carmenate, M. Delgado, and S. Gonzalez. 1997. Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Vaccine 15:751-758.
40. Muttilainen, S., I. Idänpään-Heikkilä, E. Wahlström, M. Nurminen, P. H. Mäkelä, and M. Sarvas. 1995. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native Pl epitopes. Microb. Pathog. 18:423-436.
41. Peeters, C. C., H. C. Rumke, L. C. Sundermann, E. M. Rouppe van der Voort, J. Meulenbelt, M. Schuller, A. J. Kuipers, P. van der Ley, and J. T. Poolman. 1996. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14:1009-1015.
42. Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Hoiby, E. Rosenqvist. J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:683-691.
43. Pettersson, A., B. Kuipers, M. Pelzer, E. Verhagen, R. H. Tiesjema, J. Tommassen, and J. T. Poolman. 1990. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect. Immun. 58:3036-3041.
44. Plante, M., N. Cadieux, C. R. Rioux, J. Hamel, B. R. Brodeur, and D. Martin. 1999. Antigenic and molecular conservation of the gonococcal NspA protein. Infect. Immun. 67:2855-2861.
45. Platt, M. J. 1997. Child health statistical review, 1997. Arch. Dis. Child. 77:542-548.
46. Poolman, J. T., S. de Marie, and H. C. Zanen. 1980. Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infect. Immun. 30:642-648.
47. Qiagen. 1997. Qiagen genomic DNA handbook. Qiagen, Valencia, Calif.
48. Qiagen. 1997. QIAquick handbook. Qiagen, Valencia, Calif.
49. Ramsay, M., E. Kaczmarski, M. Rush, R. Mallard, P. Farrington, and J. White. 1997. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun. Dis. Rep. Rev. 7:R49-R54.
50. Rappuoli, R. Personal communication.
51. Rosenqvist, E., E. A. Hoiby, E. Wedege, B. Kusecek, and M. Achtman. 1993. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1065-1073.
52. Rouppe van der Voort, E. M., B. Kuipers, H. F. Brugghe, L. M. van Unen, H. A. Timmermans, P. Hoogerhout, and J. T. Poolman. 1997. Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. FEMS Immunol. Med. Microbiol. 17:139-148.
53. Rümke, H. C., J. Labadie, G. van den Dobbelsteen, and L. van Alphen. 1998. Clinical studies with RIVM hexavalent meningococcal PorA vesicle vaccine, p. 58. In Abstracts of the Eleventh International Pathogenic Neisseria Conference. Editions E.D.K.
54. Russel, J. E., M. C. J. Maiden, and I. M. Feavers. 1998. Molecular analysis of antigenic variation within the porA gene of disease causing Neisseria meningitidis isolated in the United Kingdom, p. 281. In Abstracts of the Eleventh International Pathogenic Neisseria Conference. Editions E.D.K.
55. Saukkonen, K., M. Leinonen, H. Käyhty, H. Abdillahi, and J. T. Poolman. 1988. Monoclonal antibodies to the rough lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection. J. Infect. Dis. 158:209-212.
56. Scholten, R. J., H. A. Bijlmer, J. T. Poolman, B. Kuipers, D. A. Caugant, L. Van Alphen, J. Dankert, and H. A. Valkenburg. 1993. Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. Clin. Infect. Dis. 16:237-246.
57. Schuchat, A., K. Robinson, J. D. Wenger, L. H. Harrison, M. Farley, A. L. Reingold, L. Lefkowitz, and B. A. Perkins. 1997. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med. 337:970-976.
58. Seiler, A., R. Reinhardt, J. Sarkari, D. A. Caugant, and M. Achtman. 1996. Allelic polymorphism and site-specific recombination in the opc locus of Neisseria meningitidis. Mol. Microbiol. 19:841-856.
59. Stephens, D. S., J. S. Swartley, S. Kathariou, and S. A. Morse. 1991. Insertion of Tn916 in Neisseria meningitidis resulting in loss of group B capsular polysaccharide. Infect. Immun. 59:4097-4102.
60. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
61. Tettelin, H., B. A. Dougherty, E. K. Hickey, O. White, T. Mason, T. Utterback, H. O. Smith, J. C. Venter, and C. M. Fraser. 1998. Sequencing of Neisseria meningitidis serogroup B strain MC58, p. 41. In Abstracts of the Eleventh International Pathogenic Neisseria Conference. Editions E.D.K.
62. van der Ley, P., J. E. Heckels, M. Virji, P. Hoogerhout, and J. T. Poolman. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:2963-2971.
63. van der Ley, P., J. van der Biezen, and J. T. Poolman. 1995. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13:401-407.
64. van der Voort, E. R., P. van der Ley, J. van der Biezen, S. George, O. Tunnela, H. van Dijken, B. Kuipers, and J. Poolman. 1996. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64: 2745-2751.
65. Verheul, A. F., H. Snippe, and J. T. Poolman. 1993. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol. Rev. 57:34-49.
66. Virji, M., K. Makepeace, D. J, Ferguson, M. Achtman, and E. R. Moxon. 1993. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol. 10:499-510.
67. Weiss, M. S., T. Wacker, J. Weckesser, W. Welte, and G. E. Schulz. 1990. The three-dimensional structure of porin from Rhodobacter capsulatus at 3 Å resolution. FEBS Lett. 267:268-272.
68. Wenger, J. D., and B. A. Perkins. 1998. Patterns in emergence of epidemic meningococcal disease, p. 125-136. In W. M. Scheld, S. D. Armstrong, and J. M. Hughes (ed.), Emerging infectious diseases. ASM Press, Washington, D.C.
69. Zollinger, W. D., J. Boslego, L. O. Froholm, J. S. Ray, E. E. Moran, and B. L. Brandt. 1987. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie Leeuwenhoek. 53:403-411.